ARDS alone is a multi billion dollar per year addressable market, even without COVID-19.
This does not take into account the potential market contemplated within the expanded patent relating to other sepsis and inflammation conditions.
- Forums
- ASX - By Stock
- IHL
- Ann: Positive IHL-675A in vivo results and FDA Pathway
Ann: Positive IHL-675A in vivo results and FDA Pathway, page-72
-
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)